P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers

Abstract

Nectin-4, a transmembrane cell adhesion protein, is highly expressed in several epithelial tumor types, including gastrointestinal cancers; targeting Nectin-4 on these tumors may provide a novel treatment approach. Enfortumab vedotin (EV), an antibody-drug conjugate directed against Nectin-4, is comprised of a fully human monoclonal antibody specific for Nectin-4 and monomethyl auristatin E (MMAE), a microtubule-disrupting agent; targeted delivery and internalization of MMAE results in cell cycle arrest and apoptosis.